Pharmaceutical dealings after Brexit

The prospect of the UK leaving the EU, and the jurisdiction of the European’s unified single marketplace for medicinal drug regulation, is creating large uncertainty for drugmakers.

What are the regulatory implications of Brexit?

Several steps have been taken to make this a reality – most appreciably, the relocation of the EMA headquarters from London to Amsterdam – but beyond that, the total regulatory im....